Leminoprazole (NC 1300O3) is an inhibitor for acid pump, H+ K+-ATPase,. Leminoprazole stimulates the secretion and synthesis of gastric mucus, attenuates gastric ulcers. Leminoprazole is orally active[1][2][3].

Lenaldekar (LDK) inhibits human and murine T-cell expansiomn. Lenaldekar inhibits autoimmune T cell response. Lenaldekar also induces cancer cell apoptosis. Lenaldekar can be used for T-cell mediated autoimmune diseases research[1][2].

Lenalidomide 5′-piperazine is a functionalized cerebellar ligand for PROTAC development that binds an E3 ligand to terminal piperazine for subsequent chemical reactions to produce a protein deactivator with a rigid linker[1].

Lenalidomide 5′-piperazine is a functionalized cerebellar ligand for PROTAC development that binds an E3 ligand to terminal piperazine for subsequent chemical reactions to produce a protein deactivator with a rigid linker[1].

Lenalidomide 5′-piperazine is a functionalized cerebellar ligand for PROTAC development that binds an E3 ligand to terminal piperazine for subsequent chemical reactions to produce a protein deactivator with a rigid linker[1].

Lenalidomide 5′-piperazine-4-methylpiperidine hydrochloride is a functionalized cerebellar ligand for PROTAC development, combining E3 ligand and terminal piperidine for subsequent chemical reactions. A protein degradant with a rigid connector is generated[1].

Lenalidomide nonanedioic acid is a conjugate of the E3 ligase ligand and linker of LHF418 (HY-161450). Lenalidomide nonanedioic acid can be used as a key intermediate for the synthesis of intact PROTACs molecules[1].

Lenalidomide-13C5,15N is 15N and 13C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. […]

LENEP Human Pre-designed siRNA Set A contains three designed siRNAs for LENEP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LENG8 Human Pre-designed siRNA Set A contains three designed siRNAs for LENG8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lenvatinib-15N,d4 is 15N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

LEO1 Human Pre-designed siRNA Set A contains three designed siRNAs for LEO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LEP Human Pre-designed siRNA Set A contains three designed siRNAs for LEP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LEPR Human Pre-designed siRNA Set A contains three designed siRNAs for LEPR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LEPROT Human Pre-designed siRNA Set A contains three designed siRNAs for LEPROT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LEPROTL1 Human Pre-designed siRNA Set A contains three designed siRNAs for LEPROTL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Leteprinim (AIT-082 free acid), a purine analog, is a neuroprotective agent and cognitive enhancer. Leteprinim is a hypoxanthine derivative neurotrophic agent. Leteprinim can induce brain-derived neurotrophic factor (BDNF) mRNA production following spinal cord lesions, and nerve growth factor (NGF) mRNA production in basal forebrain. Leteprinim reduces glutamate toxicity in cultured hippocampal neurons. Leteprinim increases heme-oxygenase […]

LETM1 Human Pre-designed siRNA Set A contains three designed siRNAs for LETM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LETM2 Human Pre-designed siRNA Set A contains three designed siRNAs for LETM2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LETMD1 Human Pre-designed siRNA Set A contains three designed siRNAs for LETMD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Leucopyrokinin is a myotropic neuropeptide, which accelerates pupariation via central innervation, promotes tanning age dependently. Leucopyrokinin shapes the puparium by contracting and shrinking the integument[1].

Leukotriene B3 is a LTA hydrolase metabolite of LTA3 in the leukotriene biosynthesis pathway. Leukotriene B3 has proinflammatory activity[1].

Leukotriene B4 dimethyl amide, an immunomodulator, stimulates contraction of isolated guinea pig lung entities. Leukotriene B4 (LTB(4)) also stimulates human neutrophil migration, and LTB(4) antagonists may have anti-inflammatory activity in inflammatory pathophysiology[1].

Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation[1][2].

Leukotriene B4-3-aminopropylamide (LTB4-APA) is a leukotriene immunomodulator. The study found that LTB4 can bind to the polar carboxylic acid group of LTB4 near the outer surface of BLT1 cells, and the hydrophobic LTB4 tail points to the transmembrane region of the receptor protein[1].

Leupeptin Ac-LL (hydrochloride) is the hydrochloride form of Leupeptin Ac-LL (HY-18234B). Leupeptin Ac-LL (hydrochloride) has better inhibition than Leupeptin Ac-LL[1].

Levinoid C is a Cytochrome P450-modified bacterial terpenoid. Levinoid C shows moderate neuroprotective activity against glutamate-induced excitotoxicity cell model with an EC50 of 21 μM[1].

Levocetirizine (dihydrochloride) (Standard) is the analytical standard of Levocetirizine (dihydrochloride). This product is intended for research and analytical applications. Levocetirizine dihydrochloride ((R)-Cetirizine dihydrochloride) is a third-generation peripheral H1-receptor antagonist. Levocetirizine dihydrochloride is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine dihydrochloride has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can […]

LEXM Human Pre-designed siRNA Set A contains three designed siRNAs for LEXM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LFNG Human Pre-designed siRNA Set A contains three designed siRNAs for LFNG gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALS1 Human Pre-designed siRNA Set A contains three designed siRNAs for LGALS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALS2 Human Pre-designed siRNA Set A contains three designed siRNAs for LGALS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALS3 Human Pre-designed siRNA Set A contains three designed siRNAs for LGALS3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALS3BP Human Pre-designed siRNA Set A contains three designed siRNAs for LGALS3BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALS4 Human Pre-designed siRNA Set A contains three designed siRNAs for LGALS4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALS7 Human Pre-designed siRNA Set A contains three designed siRNAs for LGALS7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALS7B Human Pre-designed siRNA Set A contains three designed siRNAs for LGALS7B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALS8 Human Pre-designed siRNA Set A contains three designed siRNAs for LGALS8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALS9 Human Pre-designed siRNA Set A contains three designed siRNAs for LGALS9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALS9B Human Pre-designed siRNA Set A contains three designed siRNAs for LGALS9B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALSL Human Pre-designed siRNA Set A contains three designed siRNAs for LGALSL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGI1 Human Pre-designed siRNA Set A contains three designed siRNAs for LGI1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGI2 Human Pre-designed siRNA Set A contains three designed siRNAs for LGI2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGI3 Human Pre-designed siRNA Set A contains three designed siRNAs for LGI3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGI4 Human Pre-designed siRNA Set A contains three designed siRNAs for LGI4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.